Abstract
Invariant natural killer T cells (iNKT) and dendritic cells (DC) play a central role in tumor immunity through downstream activation of immune effector cells by pro-inflammatory cytokines. Evidence is accumulating that the CD1d-iNKT cell axis can be effectively used to potentiate DC-based cancer vaccines. Here, we provide a detailed methodology for the generation of (CD1d-expressing) monocyte-derived DC (moDC) and their subsequent loading with the iNKT cell agonist α-galactosylceramide (α-GalCer) or their direct ligation by agonistic anti-CD1d monoclonal antibodies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
van der Vliet HJ et al (2004) The immunoregulatory role of CD1d-restricted natural killer T cells in disease. Clin Immunol 112:8–23
Rossjohn J et al (2012) Recognition of CD1d-restricted antigens by natural killer T cells. Nat Rev Immunol 12:845–857
Godfrey DI et al (2004) NKT cells: what’s in a name? Nat Rev Immunol 4:231–237
Godfrey DI, Kronenberg M (2004) Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest 114:1379–1388
Wu L et al (2009) Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities. Tissue Antigens 73:535–545
Swann JB et al (2009) Type I natural killer T cells suppress tumors caused by p53 loss in mice. Blood 113:6382–6385
Bellone M et al (2010) iNKT cells control mouse spontaneous carcinoma independently of tumor-specific cytotoxic T cells. PLoS One 5:e8646
Exley MA et al (2011) Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects. Clin Immunol 140:184–195
Tahir SM et al (2001) Loss of IFN-γ production by invariant NK T cells in advanced cancer. J Immunol 167:4046–4050
Schneiders FL et al (2012) Circulating invariant natural killer T-cell numbers predict outcome in head and neck squamous cell carcinoma: updated analysis with 10-year follow-up. J Clin Oncol 30:567–570
Kawano T et al (1997) CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 278:1626–1629
Schneiders FL et al (2011) Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. Clin Immunol 140:130–141
Giaccone G et al (2002) A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 8:3702–3709
Sullivan BA, Kronenberg M (2005) Activation or anergy: NKT cells are stunned by α-galactosylceramide. J Clin Invest 115:2328–2329
van der Vliet HJ et al (2001) Potent expansion of human natural killer T cells using α-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15. J Immunol Methods 247:61–72
van der Vliet HJ et al (2003) Polarization of Vα24+ Vβ11+ natural killer T cells of healthy volunteers and cancer patients using α-galactosylceramide-loaded and environmentally instructed dendritic cells. Cancer Res 63:4101–4106
Uchida T et al (2008) Phase I study of α-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Cancer Immunol Immunother 57:337–345
Chang DH et al (2005) Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 201:1503–1517
Nieda M et al (2004) Therapeutic activation of Vα24 + Vβ11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103:383–389
Yue SC et al (2005) CD1d ligation on human monocytes directly signals rapid NF-κB activation and production of bioactive IL-12. Proc Natl Acad Sci USA 102:11811–11816
Yue SC et al (2010) Direct CD1d-mediated stimulation of APC IL-12 production and protective immune response to virus infection in vivo. J Immunol 184:268–276
Exley MA et al (2008) Selective activation, expansion, and monitoring of human iNKT cells with a monoclonal antibody specific for the TCR α-chain CDR3 loop. Eur J Immunol 38:1756–1766
Babatz J et al (2003) Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study. J Hematother Stem Cell Res 12:515–523
Gerlini G et al (2001) Cd1d is expressed on dermal dendritic cells and monocyte-derived dendritic cells. J Invest Dermatol 117:576–582
Alving CR et al (2012) Adjuvants for human vaccines. Curr Opin Immunol 24:310–315
Acknowledgements
Our work is supported by grant no. 90700309 from the Netherlands Organisation for Health Research and Development (ZonMw) and grant VU 2010–4728 from the Dutch Cancer Society (KWF).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this protocol
Cite this protocol
Lameris, R., Schneiders, F.L., de Gruijl, T.D., van der Vliet, H.J. (2014). Exploiting the CD1d-iNKT Cell Axis for Potentiation of DC-Based Cancer Vaccines. In: Lawman, M., Lawman, P. (eds) Cancer Vaccines. Methods in Molecular Biology, vol 1139. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-0345-0_14
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0345-0_14
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-0344-3
Online ISBN: 978-1-4939-0345-0
eBook Packages: Springer Protocols